ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

CINVANTI
Nausea
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

CINVANTI Rx

Generic Name and Formulations:
Aprepitant 130mg/18mL; emulsion for IV infusion after dilution; contains egg lecithin, ethanol.

Company:
Heron Therapeutics

Therapeutic Use:

Indications for CINVANTI:

In combination with other antiemetic agents to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic cancer chemotherapy, including high-dose cisplatin.

Limitations Of use:

Not studied for treating established nausea and vomiting.

Adult:

Give with dexamethasone and 5-HT3 antagonist (see full labeling). Administer approx. 30mins prior to chemotherapy. Moderately emetogenic: 100mg IV over 30mins on Day 1, then oral aprepitant 80mg on Days 2 and 3. Highly emetogenic: 130mg IV over 30mins on Day 1.

Children:

Not established.

Contraindications:

Concomitant pimozide.

Warnings/Precautions:

Severe hepatic impairment. Monitor for hypersensitivity reactions; discontinue and treat appropriately if occur; do not reinitiate if symptoms develop with first-time use. Pregnancy: not recommended. Nursing mothers.

Interactions:

See Contraindications. Monitor concomitant CYP3A4 substrates, including chemotherapy agents (eg, ifosfamide, vinblastine, vincristine). Avoid concomitant moderate-to-strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir, diltiazem) or strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). Potentiates dexamethasone (reduce its oral dose by 50%), methylprednisolone (reduce its IV dose by 25% and its oral dose by 50%), midazolam, alprazolam, triazolam. May antagonize warfarin (closely monitor INR for 2 weeks after starting each cycle), other CYP2C9 substrates, oral contraceptives (use alternative or backup methods during and for 1 month after last dose).

Pharmacological Class:

Substance P/NK1 receptor antagonist.

Adverse Reactions:

Headache, fatigue, eructation, infusion-site reactions; anaphylaxis.

Generic Availability:

NO

How Supplied:

Single-use vial—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs